Full Press Release Details
Contact: Richard L. Van Kirk, Chief Executive Officer
PRO-DEX, INC. ANNOUNCES FISCAL 2021 FIRST QUARTER RESULTS
IRVINE, CA, November 5, 2020 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2021 first quarter ended September 30, 2020. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2021 with the Securities and Exchange Commission today.
Net sales for the three months ended September 30, 2020, increased $1.4 million, or 19%, to $8.6 million from $7.2 million for the three months ended September 30, 2019. The increase is driven by sales of our newest thoracic driver.
Gross profit for the three months ended September 30, 2020, increased $695,000, or 25%, to $3.5 million, compared to $2.8 million for the year-ago period. Gross margin increased by 2 percentage points to 40% during the three months ended September 30, 2020, compared to 38% during the corresponding year-ago period due to favorable product mix and increased absorption of our fixed manufacturing overhead expenses.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2020, increased $637,000 from the corresponding year-ago period. We are increasing these expenditures in an effort to release new products and garner new customer relationships.
Net income for the quarter ended September 30, 2020, was $1.3 million, or $0.32 per diluted share, compared to $1.1 million, or $0.27 per diluted share, for the quarter ended September 30, 2019.
Richard L. ( Rick ) Van Kirk, the Company s President and Chief Executive Officer, commented, We are pleased with our first quarter results. We continue to reinvest our profits in research and development to continue to grow our core medical device business and expect to close on the purchase of a new building to expand our operations as early as tomorrow. Finally, concluded Mr. Van Kirk, we expect to introduce another CMF driver and our ENT shaver by the end of the current fiscal year.
The amount spent on projects under development, along with the current estimated commercial launch date and estimated recurring annual revenue, is summarized below (in thousands):
| For the Three Months Ended September 30, | ||||||||||||||||
| 2020 | 2019 | Market Launch (1) | Est Annual Revenue | |||||||||||||
| Total Research & Development costs: | $ | 1,091 | $ | 484 | ||||||||||||
| Products in development: | ||||||||||||||||
| Thoracic Driver (2) | $ | $ | 19 | (2) | $4,000 | |||||||||||
| Arthroscopic Shaver (3) | 6 | (3) | $ 600 | |||||||||||||
| ENT Shaver | 183 | 89 | Q2 2021 | $1,000 | ||||||||||||
| VITAL Ventilator | 57 | Q3 2021 | $1,500 | |||||||||||||
| CMF Driver | 189 | 17 | Q1 2021 | $1,000 | ||||||||||||
| Sustaining & Other | 662 | 353 | ||||||||||||||
| Total | $ | 1,091 | $ | 484 |
Represents the calendar quarter of expected market launch.
We completed the thoracic driver and began initial shipments of a private-labeled version to an existing CMF customer during the third quarter of fiscal 2020. We incurred cumulative expenditures of $1.1 million spanning from fiscal 2017 to fiscal 2020 related to this product development. Current thoracic related expenditures are included in sustaining and other. We generated sales from this product of $3.1 million and $1.6 million during fiscal 2020 and the first quarter of fiscal 2021, respectively. Accordingly, we will remove this product from the above table next quarter.
This product has been internally pushed back to focus on our Pro-Dex branded ENT shaver. Accordingly, we will remove this product from the above table next quarter until such time as we reinstate this project.
In the fourth quarter of fiscal 2020, we were one of eight US-based companies awarded a license to manufacture the Jet Propulsion Laboratory s Ventilator Intervention Technology Accessible Locally ( VITAL ), a high-pressure, lower cost ventilator. In order to manufacture this product, we will require a full clean room, which we plan to install in our Tustin facility (assuming we close on the property, which is expected to occur on or around November 6, 2020). We are also nearing completion on the verification and validation of a new CMF driver, which we will be selling to our existing largest customer under a distribution agreement, that we executed in the first quarter of fiscal 2021. Finally, we also anticipate the release to manufacture of a new ENT Shaver in the spring of 2021 and our Director of Business Development is working with a promising medical device distributor to commercialize this product.
About Pro-Dex, Inc.:
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Pro-Dex also sells compact pneumatic air motors for a variety of industrial applications. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.
Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the risk factors and other disclosures concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.
CONDENSED BALANCE SHEETS
(In thousands, except share amounts)
| September 30, 2020 | June 30, 2020 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 5,202 | $ | 6,421 | ||||
| Investments | 2,400 | 2,560 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $9 and $6 at September 30, 2020 and at June 30, 2020, respectively | 6,138 | 5,155 | ||||||
| Deferred costs | 142 | 155 | ||||||
| Inventory | 8,313 | 8,238 | ||||||
| Prepaid expenses and other current assets | 343 | 145 | ||||||
| Total current assets | 22,538 | 22,674 | ||||||
| Equipment and leasehold improvements, net | 2,629 | 2,686 | ||||||
| Right of use asset, net | 2,861 | 2,943 | ||||||
| Intangibles, net | 159 | 162 | ||||||
| Deferred income taxes, net | 259 | 259 | ||||||
| Investments | 2,309 | 2,360 | ||||||
| Other assets | 42 | 42 | ||||||
| Total assets | $ | 30,797 | $ | 31,126 | ||||
| LIABILITIES AND SHAREHOLDERS EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 1,834 | $ | 1,965 | ||||
| Accrued expenses | 1,757 | 2,411 | ||||||
| Deferred revenue | 200 | 200 | ||||||
| Note payable and capital lease obligations | 660 | 651 | ||||||
| Total current liabilities | 4,451 | 5,227 | ||||||
| Lease liability, net of current portion | 2,695 | 2,750 | ||||||
| Income taxes payable | 486 | 804 | ||||||
| Notes and capital leases payable, net of current portion | 3,114 | 3,283 | ||||||
| Total non-current liabilities | 6,295 | 6,837 | ||||||
| Total liabilities | 10,746 | 12,064 | ||||||
| Shareholders Equity: | ||||||||
| Common shares; no par value; 50,000,000 shares authorized; 3,858,251 and 3,811,137 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively | 12,583 | 12,752 | ||||||
| Accumulated other comprehensive loss | (1,693 | ) | (1,586 | ) | ||||
| Retained earnings | 9,161 | 7,896 | ||||||
| Total shareholders equity | 20,051 | 19,062 | ||||||
| Total liabilities and shareholders equity | $ | 30,797 | $ | 31,126 |
CONDENSED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE INCOME
(In thousands, except share and per share amounts)
| Three Months Ended September 30, | ||||||||
| 2020 | 2019 | |||||||
| Net sales | $ | 8,590 | $ | 7,240 | ||||
| Cost of sales | 5,115 | 4,460 | ||||||
| Gross profit | 3,475 | 2,780 | ||||||
| Operating expenses: | ||||||||
| Selling expenses | 130 | 142 | ||||||
| General and administrative expenses | 705 | 663 | ||||||
| Research and development costs | 1,091 | 484 | ||||||
| Total operating expenses | 1,926 | 1,289 | ||||||
| Operating income | 1,549 | 1,491 | ||||||
| Other income (expense): | ||||||||
| Interest and miscellaneous income | 53 | 35 | ||||||
| Interest expense | (54 | ) | (59 | ) | ||||
| Total other income (expense) | (1 | ) | (24 | ) | ||||
| Income before income taxes | 1,548 | 1,467 | ||||||
| Provision for income taxes | 283 | 363 | ||||||
| Net income | 1,265 | 1,104 | ||||||
| Other comprehensive income (loss), net of tax: | ||||||||
| Unrealized loss from marketable equity investments, net of taxes | (107 | ) | (57 | ) | ||||
| Comprehensive income | $ | 1,158 | $ | 1,047 | ||||
| Basic and diluted income per share: | ||||||||
| Basic net income per share | $ | 0.33 | $ | 0.28 | ||||
| Diluted net income per share | $ | 0.32 | $ | 0.27 | ||||
| Weighted average common shares outstanding: | ||||||||
| Basic | 3,850,838 | 4,008,017 | ||||||
| Diluted | 3,975,063 | 4,110,414 | ||||||
| Common shares outstanding | 3,858,251 | 3,990,995 |